



RESULTS UPDATE

Healthcare

Fair value: SEK2.10–3.50

Share price: SEK1.59

Alzinova

Progress hinges on partnership execution – Q3 review

Research analysts:

Maria Karlsson Osipova
DNB Carnegie Investment Bank AB

The Q3 report was fairly undramatic, but financing pressure continues to mount. Our new fair value range is SEK2.1–3.5 per share (SEK2.8–4.6).

Financing pressure mounts as partnership remains unresolved. This was a fairly undramatic report, with EBIT of SEK-7m (Q3 2024 SEK-4m) and operating cash flow of SEK-5m (Q3 2024 SEK-2m). Cash at end-Q3 amounted to SEK0.5m. Earlier this fall, Alzinova entered short-term loan agreements, extending the cash runway into Q1 2026, according to the company.

News flow in Q4 to date. In October, Alzinova announced that the FDA had granted Fast Track Designation for ALZ-101, following encouraging safety and early efficacy data from the completed Phase Ib trial. Earlier in November, the company also announced its participation with two poster presentations at the Clinical Trials on Alzheimer's Disease (CTAD) conference in early December – one of the leading global scientific meetings focused on the latest advances in Alzheimer's drug development and clinical research. We believe presenting at CTAD is clearly positive for visibility within the Alzheimer's research community. The two poster presentations are set to focus on clinical data from the Phase Ib study of ALZ-101, as well as on new biomarker findings showing the presence of naturally occurring antibodies against neurotoxic Aβ oligomers.

New fair value range SEK2.1–3.5 per share (SEK2.8–4.6). We believe investors are primarily awaiting the announcement of a partnership agreement. According to the company, partnership discussions remain active, but we were not provided with any other information in the Q3 report since such processes are typically highly confidential. While we find it encouraging that outreach efforts continue and may pave the way for future collaborations, encouraging signals alone are not enough given the current financial pressure. Until a partnership materialises, we expect the financing overhang to continue weighing on the name. Reflecting the continued high financing risk, despite the short-term loan arrangement, we have raised our WACC from 16–20% to 18–22%. Our new fair value range is SEK2.1–3.5 per share.

Changes in this report				Key figures (SEK)					Share price – 5-year	
	From	To	Chg		2024	2025e	2026e	2027e		
EPS adj. 2025e	-0.34	-0.23	+31%	Sales (m)	0	0	0	0		
EPS adj. 2026e	-0.62	-0.63	-3%	EBITDA (m)	-20	-28	-83	-93		
EPS adj. 2027e	-0.69	-0.71	-3%	EBIT (m)	-20	-28	-83	-93		
Upcoming events				EPS	-0.31	-0.23	-0.63	-0.71		
Q4 Report		26 Feb 2026		EPS adj.	-0.31	-0.23	-0.63	-0.71		
				DPS	0.00	0.00	0.00	0.00		
				Sales growth Y/Y	-chg	n.a.	n.a.	n.a.		
				EPS adj. growth Y/Y	+chg	+chg	-chg	-chg		
				EBIT margin	n.m.	n.m.	n.m.	n.m.		
				P/E adj.	n.m.	n.m.	n.m.	n.m.		
Key facts				EV/EBIT	neg.	neg.	neg.	neg.	High/Low (12M) SEK4.1/1.1	
No. shares (m)		104.3		EV/EBITA	neg.	neg.	neg.	neg.		
Market cap. (USDm)		18		EV/EBITDA	neg.	neg.	neg.	neg.		
Market cap. (SEKm)		166		P/BV	1.1	1.3	0.9	0.8		
Net IB Debt. (SEKm)		9		Dividend yield	0.0%	0.0%	0.0%	0.0%		
Adjustments (SEKm)		0		FCF yield	-22.4%	-29.0%	-58.0%	-62.6%		
EV (2025e) (SEKm)		175		Equity/Total Assets	92.9%	91.4%	99.6%	99.6%		
Free float		81.8%		ROCE	-17.2%	-21.7%	-52.5%	-48.1%		
Avg. daily vol. ('000)		665		ROE adj.	-17.3%	-18.1%	-43.4%	-38.4%		
BBG		ALZ SS		Net IB debt/EBITDA	0.7	-0.3	0.2	0.1		
Fiscal year end		December							Perf. 3M 6M 12M YTD Abs. 34.29 -16.32 -58.81 -54.05 Rel. 28.83 -23.06 -66.03 -62.10	
Share price as of (CET)	13 Nov 2025	16:00								

Source: DNB Carnegie (estimates), FactSet, Infront & company data

This report has been commissioned and sponsored by Alzinova. Commissioned research is considered to be marketing communication (i.e. not investment research under MiFID II). This material may be subject to restrictions on distribution in certain areas.

Equity story

Near term: within 12M

Alzinova is actively engaged in partnership discussions concerning a potential licensing agreement for ALZ-101. In our view, this represents the most important potential near-term catalyst for the share price.

Long-term outlook: 5Y+

The long-term story for Alzinova centres on ALZ-101 demonstrating encouraging clinical data and eventually achieving market approval. The high prevalence of Alzheimer's disease, combined with the substantial healthcare costs it entails, creates considerable market potential for disease-modifying therapies. GlobalData expects the Alzheimer's treatment market to expand at a 23.4% CAGR through 2033.

Key risks:

- Early-stage clinical development companies face significant risks, including failure in planned studies, regulatory hurdles, and uncertainty regarding study timing and results. Such risks are generally high at this stage of development.
- Alzheimer's disease clinical trials require lengthy follow-up periods, posing recruitment and timing risks.
- The company is likely to need more capital before reaching breakeven.

Company description

Alzinova is a Swedish clinical-stage biopharmaceutical company developing a therapeutic vaccine and monoclonal antibody against Alzheimer's disease. The company identified a method that could specifically target the toxic elements in the brain – amyloid-beta oligomers – one of the underlying causes of Alzheimer's disease.

Key industry drivers

- Ageing population
- New innovative therapies
- Advancements in biomarkers and diagnostics

Industry outlook

- We expect the Alzheimer's sector to experience robust growth, driven by emerging therapeutic targets, novel treatment modalities, and a supportive regulatory environment.

Largest shareholders, capital

Maida Vale Capital AB	16.5%
Avanza Pension	7.4%
Nordnet Pensionsförsäkring	3.8%

Cyclicality

Cyclicality: No
Not cyclical


Key peers

BioArctic, Alzecure Pharma

Valuation and methodology

We use a sum-of-the-parts approach in our valuation of Alzinova, with different DCFs for the top and bottom of the fair value range. In our model, we project peak sales of USD3.2bn for ALZ-101 in Alzheimer's disease. We assign the project a 12% likelihood of approval (LoA). Due to the absence of completed clinical trials, we have not yet included ALZ-201 in our valuation model.


Fair value range 12M



The lower end of our fair value range is derived from our SOTP model using a DCF with a WACC of 22%, reflecting a scenario where the company delivers on our expectations but broader sentiment toward biotech remains subdued.

The upper end, based on a WACC of 18%, assumes the same operational performance but with improving sector sentiment. We apply a relatively high WACC to capture the financing risk overhang, as the company will likely need to raise additional capital to initiate its Phase II trial should a partnership agreement not materialise.

Key metrics



P/E 12-months forward



Long-term valuation trend



Source: DNB Carnegie (estimates) & company data

Valuation

We continue to use a sum-of-the-parts (SOTP) approach in our valuation of Alzinova, with two DCFs for the lower and upper ends of our fair value range. In our model, we project peak sales of USD3.2bn for ALZ-101 in Alzheimer's disease. We assign the project a 12% LoA.

Due to the absence of completed clinical trials, we have not yet included ALZ-201 in our valuation model. Our assumptions include a partnership deal for ALZ-101 in 2028 with a total value of USD1bn, comprising an upfront payment of USD100m, contingent on positive top-line results from the Phase II trial. Additionally, we estimate Alzinova will receive 15% of net sales for ALZ-101.

While we acknowledge it is possible that the company will sign a licensing deal ahead of a Phase II trial, we do not factor this into our model. We assume the company will need to raise >SEK200m in total to finance a Phase II trial.

We raise our WACC assumption from 16–20% to 18–22% to reflect increased financing risk. While the company continues to explore partnership and funding options, the absence of concrete progress combined with a challenging capital market environment heightens uncertainty around near-term financing. Our new fair value range is SEK2.1–3.5 per share (SEK2.8–4.6). The lower end of our fair value range is based on our DCF model using a WACC of 22%, and the upper end is based on our DCF model using a WACC of 18%.

SOTP valuation – lower and higher end of the valuation range

Project	Launch	Peak sales (USDm)	LOA (%)	WACC (%)	NPV (SEKm)	NPV per share (SEK)
ALZ-101, Alzheimer's disease	2032e	3,222	12%	22%	273	3
Unallocated costs (SEKm)					-48	0
Enterprise value (SEKm)					224	2
Net cash Q3 2025					0	0
Total NPV					224	2.1

Project	Launch	Peak sales (USDm)	LOA (%)	WACC (%)	NPV (SEKm)	NPV per share (SEK)
ALZ-101, Alzheimer's disease	2032e	3,222	12%	18%	427	4
Unallocated costs (SEKm)					-57	-1
Enterprise value (SEKm)					371	4
Net cash Q3 2025					0	0
Total NPV					370	3.5

Source: DNB Carnegie

NPV/share sensitivity analysis, WACC (%) and LoA (%)

		LOA (%)				
		10%	12%	14%	16%	18%
WACC (%)	14%	4.4	5.7	6.6	7.7	8.9
	16%	3.4	4.5	5.3	6.2	7.1
	18%	2.6	3.5	4.2	5.0	5.7
	20%	2.0	2.8	3.3	4.0	4.6
	22%	1.5	2.1	2.6	3.1	3.7

Source: DNB Carnegie

Short-term loan arrangement

So far in Q4, Alzinova has entered into SEK11m short-term loan agreements with two external lenders to cover working capital needs through FY 2025 and into Q1 2026. The loan carries a 5% arrangement fee and 1.5% monthly interest, maturing on 31 March 2026, with optional early repayment. If unpaid at maturity, lenders may require a SEK45m rights issue to repay the debt, with Maida Vale Capital (the company's largest shareholder) committed to participating in and guaranteeing any remaining amount. Combined with the previously announced SEK10m loan promise from Maida Vale, the arrangement extends Alzinova's financial runway, providing flexibility to advance partnership discussions and development milestones following the FDA Fast Track Designation for ALZ-101.

As we wrote in our news comment in October, we believe that while the loan provides additional liquidity through FY 2025 and into Q1 2026, it is quite costly (5% arrangement fee and 1.5% monthly interest). The facility also comes with a dilution overhang where lenders may trigger a SEK45m rights issue if the loan is not repaid by March 2026. Following the SEK30m rights issue earlier this year, we had expected Alzinova to be funded through Phase II trial preparations, but not the execution of the trial itself.

We continue to believe that additional funding would be required should the company proceed with the Phase II trial independently, should a partnership agreement not materialise.

Risks

Clinical development risk. In terms of companies in early clinical development, the greatest risk is always that they fail in their planned clinical studies or do not receive approval to begin such studies. There is also a risk that the authorities do not approve an application for clinical studies or to advance further with ongoing studies. Both pre-clinical and clinical studies are associated with considerable uncertainty, as well as risks with their timing or results.

Risks related to patient recruitment or delays. The Alzheimer's field is known for its lengthy follow-up periods for clinical studies. This entails risk with both patient recruitment and delays.

Risks related to key staff. The company has a compact management structure and is highly dependent on key executives. If it were to lose some of its key staff, this would damage the company's future development.

Commercialisation risk. The company has not yet commercialised any projects, such as via licensing deals, partnerships, or through its own development, or launched any drugs. It thus has not made any sales or generated any revenues.

Financial risks. While the company has secured a short-term bridge loan facility, we believe that, given its current cash position, additional funding will be required to sustain operations unless a licensing agreement is signed. There are no guarantees that the company will be able to raise the necessary capital on favourable terms – or at all – and failure to do so could ultimately force it to cease operations.

Financial statements

Profit & loss (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Sales	0	0	0	0	0	0	0	0	0	0
COGS	0	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	0	0	0
Other income & costs	0	0	-6	-8	-13	-17	-20	-28	-83	-93
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
EBITDA	0	0	-6	-8	-13	-17	-20	-28	-83	-93
Depreciation PPE	0	0	0	0	0	0	0	0	0	0
Depreciation lease assets	0	0	0	0	0	0	0	0	0	0
Amortisation development costs	0	0	0	0	0	0	0	0	0	0
Amortisation other intangibles	0	0	0	0	0	0	0	0	0	0
Impairments / writedowns	0	0	0	0	0	0	0	0	0	0
EBITA	0	0	-6	-8	-13	-17	-20	-28	-83	-93
Amortization acquisition related	0	0	0	0	0	0	0	0	0	0
Impairment acquisition related	0	0	0	0	0	0	0	0	0	0
EBIT	0	0	-6	-8	-13	-17	-20	-28	-83	-93
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
Net financial items	0	0	0	0	0	0	0	0	0	0
of which interest income/expenses	0	0	0	0	0	0	0	0	0	0
of which interest on lease liabilities	0	0	0	0	0	0	0	0	0	0
of which other items	0	0	0	0	0	0	0	0	0	0
Pre-tax profit	0	0	-6	-8	-13	-16	-21	-28	-83	-93
Taxes	0	0	0	0	0	0	0	6	17	19
Post-tax minorities interest	0	0	0	0	0	0	0	0	0	0
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Net profit	0	0	-6	-8	-13	-16	-21	-23	-66	-74
Adjusted EBITDA	0	0	-6	-8	-13	-17	-20	-28	-83	-93
Adjusted EBITA	0	0	-6	-8	-13	-17	-20	-28	-83	-93
Adjusted EBIT	0	0	-6	-8	-13	-17	-20	-28	-83	-93
Adjusted net profit	0	0	-6	-8	-13	-16	-21	-23	-66	-74
Sales growth Y/Y	na	na	na	na	na	+chg	-chg	na	na	na
EBITDA growth Y/Y	na	na	-chg	-chg	-chg	-chg	-chg	-chg	-chg	-chg
EBITA growth Y/Y	na	na	-chg	-chg	-chg	-chg	-chg	-chg	-chg	-chg
EBIT growth Y/Y	na	na	-chg	-chg	-chg	-chg	-chg	-chg	-chg	-chg
EBITDA margin	nm	nm	nm	nm	nm	na	nm	nm	nm	nm
EBITA margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
EBIT margin	nm	nm	nm	nm	nm	na	nm	nm	nm	nm
Tax rate	na	na	na	na	na	na	na	20.6%	20.6%	20.6%
Cash flow (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
EBITDA	0	0	-6	-8	-13	-17	-20	-28	-83	-93
Paid taxes	0	0	0	0	0	0	0	6	17	19
Change in NWC	0	0	0	-2	3	1	0	-6	0	0
Interests paid	0	0	0	0	0	0	0	0	0	0
Actual lease payments	0	0	0	0	0	0	0	0	0	0
Non cash adjustments	0	0	0	0	0	0	0	0	0	0
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Total operating activities	0	0	-6	-10	-10	-15	-20	-28	-66	-74
Capex tangible assets	0	0	0	0	0	0	0	0	0	0
Capitalised development costs	0	0	-15	-17	-17	-20	-17	-20	-30	-30
Capex - other intangible assets	0	0	0	0	0	0	0	0	0	0
Acquisitions/divestments	0	0	0	0	0	0	0	0	0	0
Other non-cash adjustments	0	0	0	0	0	0	0	0	0	0
Total investing activities	0	0	-15	-17	-17	-20	-17	-20	-30	-30
Dividend paid and received	0	0	0	0	0	0	0	0	0	0
Share issues & buybacks	0	0	43	0	30	25	31	24	120	100
Change in bank debt	0	0	0	0	0	0	0	11	-11	0
Other cash flow items	0	0	0	0	0	0	0	0	0	0
Total financing activities	0	0	43	0	30	25	31	35	109	100
Operating cash flow	0	0	-6	-10	-10	-15	-20	-28	-66	-74
Free cash flow	0	0	-21	-27	-27	-35	-37	-48	-96	-104
Net cash flow	0	0	22	-27	3	-10	-7	-13	13	-4
Change in net IB debt	0	0	22	-27	3	-10	-7	-24	24	-4
Capex / Sales	nm	nm	nm	nm	nm	0.0%	nm	nm	nm	nm
NWC / Sales	nm	nm	nm	nm	nm	-1796.5%	nm	nm	nm	nm

Source: DNB Carnegie (estimates) & company data

Financial statements, cont.

Balance sheet (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Acquired intangible assets	0	0	0	0	0	0	0	0	0	0
Other fixed intangible assets	0	0	2	2	2	2	2	2	2	2
Capitalised development	0	0	43	60	77	96	113	133	163	193
Tangible assets	0	0	0	0	0	0	0	0	0	0
Lease assets	0	0	0	0	0	0	0	0	0	0
Other IB assets (1)	0	0	0	0	0	0	0	0	0	0
Other non-IB assets	0	0	0	0	0	0	0	0	0	0
Fixed assets	0	0	44	62	78	98	115	135	165	195
Inventories (2)	0	0	0	0	0	0	0	0	0	0
Receivables (2)	0	0	0	0	0	0	0	0	0	0
Prepaid exp. & other NWC items (2)	0	0	0	1	1	3	3	0	0	0
IB current assets (1)	0	0	0	0	0	0	0	0	0	0
Other current assets	0	0	0	0	0	0	0	0	0	0
Cash & cash equivalents (1)	0	0	56	29	32	22	15	3	16	12
Current assets	0	0	56	30	33	25	19	3	16	12
Total assets	0	0	101	92	112	123	133	137	180	206
Shareholders' equity	0	0	96	88	106	114	124	126	179	206
Minorities	0	0	0	0	0	0	0	0	0	0
Other equity	0	0	0	0	0	0	0	0	0	0
Total equity	0	0	96	88	106	114	124	126	179	206
Deferred tax	0	0	0	0	0	0	0	0	0	0
LT IB debt (1)	0	0	1	1	1	1	1	1	1	1
Other IB provisions (1)	0	0	0	0	0	0	0	0	0	0
Lease liabilities	0	0	0	0	0	0	0	0	0	0
Other non-IB liabilities	0	0	0	0	0	0	0	0	0	0
LT liabilities	0	0	1	1	1	1	1	1	1	1
ST IB debt (1)	0	0	0	0	0	0	0	11	0	0
Payables (2)	0	0	2	2	3	2	3	0	0	0
Accrued exp. & other NWC items (2)	0	0	2	2	2	6	6	0	0	0
Other ST non-IB liabilities	0	0	0	0	0	0	0	0	0	0
Liabilities - assets held for sale	0	0	0	0	0	0	0	0	0	0
Current liabilities	0	0	4	3	5	9	9	11	0	0
Total equity and liabilities	0	0	101	93	112	123	133	137	180	206
Net IB debt (=1)	0	0	-55	-28	-31	-21	-15	9	-15	-11
Net working capital (NWC) (=2)	0	0	-4	-2	-4	-6	-6	0	0	0
Capital employed (CE)	0	0	97	89	106	115	125	137	180	206
Capital invested (CI)	0	0	-2	-1	-3	-4	-4	2	2	2
Equity / Total assets	nm	nm	95%	96%	95%	92%	93%	91%	100%	100%
Net IB debt / EBITDA	nm	nm	8.5	3.7	2.4	1.3	0.7	-0.3	0.2	0.1
Per share data (SEK)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Adj. no. of shares in issue YE (m)	0.00	0.00	15.78	15.78	32.42	44.53	89.17	104.3	104.3	104.3
Diluted no. of Shares YE (m)	0.00	0.00	15.78	15.78	32.42	44.53	89.17	104.3	104.3	104.3
EPS	na	na	-0.82	-0.48	-0.54	-0.43	-0.31	-0.23	-0.63	-0.71
EPS adj.	na	na	-0.82	-0.48	-0.54	-0.43	-0.31	-0.23	-0.63	-0.71
CEPS	na	na	-0.82	-0.48	-0.54	-0.43	-0.31	-0.23	-0.63	-0.71
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
BVPS	na	na	6.09	5.61	3.26	2.56	1.39	1.20	1.72	1.97
Performance measures	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
ROE	nm	nm	-13.5%	-8.2%	-13.5%	-15.0%	-17.3%	-18.1%	-43.4%	-38.4%
Adj. ROCE pre-tax	na	na	na	-8.1%	-13.4%	-14.9%	-17.2%	-21.7%	-52.5%	-48.1%
Adj. ROIC after-tax	na	na	na	565.9%	801.1%	513.4%	506.6%	1770.0%	-4057.6%	-4524.6%
Valuation	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
FCF yield	0.0%	0.0%	-12.8%	-16.4%	-16.3%	-21.0%	-22.4%	-29.0%	-58.0%	-62.6%
Dividend yield YE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Dividend payout ratio	na	na	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Dividend + buy backs yield YE	nm	nm	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EV/Sales YE	nm	nm	nm	nm	nm	>50	nm	nm	nm	nm
EV/EBITDA YE	nm	nm	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
EV/EBITA YE	nm	nm	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
EV/EBITA adj. YE	nm	nm	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
EV/EBIT YE	nm	nm	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
P/E YE	na	na	nm	nm	nm	nm	nm	nm	nm	nm
P/E adj. YE	na	na	nm	nm	nm	nm	nm	nm	nm	nm
P/BV YE	na	na	0.92	0.83	0.69	0.96	2.49	1.32	0.92	0.81
Share price YE (SEK)	13.0	7.52	5.58	4.67	2.24	2.46	3.46	1.59		

Source: DNB Carnegie (estimates) & company data

Disclosures and disclaimers

DNB Carnegie

DNB Carnegie is a Business Area in the DNB Group comprising: 1) the investment services division of DNB Bank ASA; 2) DNB Carnegie Investment Bank AB (a wholly owned subsidiary of DNB Bank ASA) and 3) DNB Carnegie, Inc. (a wholly owned subsidiary of DNB Bank ASA). DNB Carnegie is a leading Nordic provider of investment services.

DNB Carnegie generates added value for institutions, companies and private clients in the areas of trading in securities, investment banking, and securities services.

The research of DNB Carnegie is produced in the investment services division of DNB Bank ASA and DNB Carnegie Investment Bank AB; thus "DNB Carnegie" should be read as meaning these two entities throughout the disclaimer text, unless otherwise expressly stated.

General

This research report has been prepared by DNB Carnegie and is based on information obtained from various public sources that DNB Carnegie believes to be reliable but has not independently verified, and DNB Carnegie makes no guarantee, representation or warranty as to its accuracy or completeness.

This research report does not, and does not attempt to, contain everything material that there is to be said about the company. Any opinions expressed herein reflect DNB Carnegie's judgement at the time this research report was prepared and are subject to change without notice.

DNB Bank ASA, its affiliates and subsidiaries, their directors, officers, shareholders, employees or agents, are not responsible for any errors or omissions, regardless of the cause, or for the results obtained from the use of this research report, and shall in no event be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of this research report.

Any use of non-DNB Carnegie logos in this research report is solely for the purpose of assisting in identifying the relevant party. DNB Carnegie is not affiliated with any such party.

DNB Carnegie produces and distributes research reports from 1) the investment services division of DNB Bank ASA; and 2) DNB Carnegie Investment Bank AB (a wholly owned subsidiary of DNB Bank ASA). Clients receiving research reports from DNB Carnegie will therefore receive research reports produced by both companies. This research report is produced in the DNB Carnegie company where the responsible analyst is employed, please see the responsible analyst's name and DNB Carnegie company on the front page under the analyst's name to determine in which DNB Carnegie company this research report is produced.

This research report is distributed in Norway, the US, Singapore, Canada and Australia by the investment services division of DNB Bank ASA; in Sweden, Finland and Denmark by DNB Carnegie Investment Bank AB (a wholly owned subsidiary of DNB Bank ASA); and in the UK by the investment services division of DNB Bank ASA and DNB Carnegie Investment Bank AB, respectively.

DNB Carnegie is under supervision

DNB Bank ASA is a bank incorporated in Norway and is authorised and regulated by the Norwegian Financial Supervisory Authority. DNB Bank ASA is established in Singapore and in the UK via its Singapore and UK branches, which are authorised and regulated by the Monetary Authority of Singapore, and on a limited basis by the Financial Conduct Authority and the Prudential Regulation Authority of the UK respectively. DNB Bank ASA is established in Sweden via its Sweden branch which are subject to supervision by the Financial Supervisory Authority of Sweden. DNB Carnegie Investment Bank AB is a bank incorporated in Sweden with limited liability and is authorised and regulated by the Swedish Financial Supervisory Authority. DNB Carnegie Investment Bank AB is established in the UK via its UK branch which is authorised and regulated by the UK Financial Conduct Authority (FCA). DNB Carnegie Investment Bank AB is established in Finland and Denmark via its Finland and Denmark branches which are subject to limited supervision by the respective national Supervisory Authorities.

Further details about the extent of regulation by local authorities outside Norway and Sweden are available on request.

Property rights

This research report is for clients only, and not for publication, and has been prepared for information purposes by DNB Carnegie.

This research report is the property of DNB Carnegie. DNB Carnegie retains all intellectual property rights (including, but not limited to, copyright) relating to this research report. Sell-side investment firms are not allowed any commercial use (including, but not limited to, reproduction and redistribution) of this research report contents, either partially or in full, without DNB Carnegie's explicit and prior written consent. However, buy-side investment firms may use this research report when making investment decisions, and may also base investment advice given to clients on this research report. Such use is dependent on the buy-side investment firm citing DNB Carnegie as the source.

The Report does not constitute investment advice

This research report is made for information purposes only, and does not constitute and should not in any way be considered as an offer to buy or sell any securities or other financial instruments or to participate in any investment strategy. This research report has been prepared as general information and is therefore not intended as a personal recommendation of particular financial instruments or strategies, and does not constitute personal investment advice. Investors should therefore make their own assessments of whether any of the trading ideas described herein are a suitable investment based on the investor's knowledge and experience, financial situation, and investment objectives.

Risk warning

The risk of investing in financial instruments is generally high. Past performance is not a reliable indicator of future performance, and estimates of future performance are based on assumptions that may not be realised. When investing in financial instruments, the value of the investment may increase or decrease, and the investor may lose all or part of their investment. Careful consideration of possible financial distress should be made before investing in any financial instrument.

Analyst certification

The research analyst(s) responsible for the content of this research report certify that: 1) the views expressed in this research report accurately reflect that research analyst's personal views about the company and the securities that are the subject of this research report; and 2) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this research report. DNB Carnegie employees, including research analysts, may receive compensation that is generated by overall firm profitability.

Type of coverage, including valuation methodologies and assumptions

1. Fundamental analysis with a target price and recommendation. DNB Carnegie publishes a target price for most of the stocks in our Research Universe. The target price is the analyst's assessment of expected total return (including dividend per share) over the coming 12 months based on various fundamental valuation methods. The target price is based on a combination of several valuation methods such as discounted cash flow, pricing based on earnings multiples, multiple on book value, net asset value and peer comparison. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E and EV/EBIT, relative to industry peers to obtain a target price. For companies where it is appropriate, a target price can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Target prices are revised when earnings and cash flow forecasts are changed. Thus, changes to estimates are a key risk to the target price. Other reasons for revising target prices include changes in the underlying value of a company's assets and when factors affecting the required rate of return change, which can also be seen as risk factors to the target price.

2. Quantitative and technical analysis. DNB Carnegie produces research based on quantitative and technical analysis ("quant products"). Such research is based on mathematical and technical models applied to companies, industries and sectors, rather than a fundamental analysis of a company. Quantitative and technical analysis thus does not result in estimates, a valuation or a recommendation (e.g. BUY, SELL, HOLD). Quant products may also have a significantly different time horizon from those of other products generated by DNB Carnegie. The views expressed in quant products may thus differ from, or conflict with, those presented in other research reports generated by DNB Carnegie.

3. Commissioned research reports include the analyst's assessment of a fair value range over the coming 6-12 months based on various fundamental valuation methods. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E and EV/EBIT, relative to industry peers. For companies where it is appropriate, a fair value range can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Fair value ranges represent the assessment of the analyst(s) at the time of writing.

You will find detailed information about the valuation or methodology, the underlying assumptions, and risks on DNB Carnegie Edge (www.edge.carnegie.se). The complete history of equity research reports and previous recommendations can also be found on DNB Carnegie Edge and here.

Frequency of update

DNB Carnegie's research analysis consists of case-based analyses, meaning the frequency of the analytical research report may vary over time. Unless otherwise expressly stated in this research report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

Potential conflicts of interest

DNB Carnegie may from time to time perform or solicit investment banking services for any company mentioned in this research report. Any such publicly announced business activity during the past 12 months will be referred to in the company-specific disclosures.

Readers should assume that any company mentioned in this research report may have an active client relationship with DNB Carnegie which is not disclosed due to client confidentiality e.g. trading in securities. Readers should also assume that DNB Carnegie may provide registrar services to the company, and/or assist with new issuance of bonds where the process is handled by Fixed Income Sales only.

DNB Bank ASA, its affiliates and subsidiaries are engaged in commercial banking activities, and may for example be a lender to any company mentioned in this research report. This means that certain parts of these entities might have access to whatever rights and information regarding addressed companies as are available to a creditor under applicable law and the applicable loan and credit agreements.

DNB Carnegie and the rest of DNB Group have implemented a set of rules handling conflicts of interest. This includes confidentiality rules restricting the exchange of information between various parts of DNB Carnegie and the rest of DNB group. In order to restrict flows of sensitive information, appropriate information barriers have been established between the Investment Banking Division and other business departments in DNB Carnegie, and between DNB Carnegie and other business areas in the DNB Group. People outside an information barrier may gain access to sensitive information only after having observed applicable wall-crossing procedures. This means that employees of DNB Carnegie who are preparing the research reports are prevented from using or being aware of information available in other parts of DNB Carnegie or DNB Group that may be relevant to the recipients' decisions.

The remuneration of employees involved in preparing this research report is not tied to investment banking transactions performed by DNB Carnegie or a legal person within the same group.

Confidential and non-public information regarding DNB Carnegie and its clients, business activities and other circumstances that could affect the market value of a security ("sensitive information") is kept strictly confidential and may never be used in an undue manner. Internal guidelines are implemented to ensure the integrity and independence of research analysts. In accordance with the guidelines, the research department is separated from the Investment Banking department and there are no reporting lines between the research department and Investment Banking. The guidelines also include rules regarding, but not limited to, the following issues: contacts with covered companies, prohibition against offering favourable recommendations, personal involvement in covered companies, participation in investment banking activities, supervision and review of research reports, analyst reporting lines, and analyst remuneration.

DNB Carnegie and any of its officers or directors may have a position, or otherwise be interested in, transactions in securities that are directly or indirectly the subject of this research report. Any significant financial interests held by the analyst, DNB Carnegie, or a legal person in the same group in relation to the issuer will be referred to in the company-specific disclosures.

Other material conflicts of interest: Commissioned Research

This research report was commissioned and sponsored by the issuer (issuer-paid research) and should therefore be considered marketing communication (i.e. not investment research).

Payment for this research report has been agreed in advance on a non-recourse basis. As commissioned research, this research report can be considered an acceptable minor non-monetary benefit under MiFID II. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, it is still subject to the same confidentiality rules and sound research principles.

Commissioned research is intended only for professional investors. Such investors are expected to make their own investment decisions without undue reliance on this research report.

Company specific disclosures

The following disclosures relate to relationships between DNB Carnegie Investment Bank AB (with its subsidiaries, "DNB Carnegie") and the subject company.

Please see edge.dnbcarnegie.se/legal/disclosuresanddisclaimers for equity disclosures and historical recommendation and target price information on all companies covered by DNB Carnegie.

**Additional information for clients in Australia**

This research report has been prepared and issued outside Australia.

DNB Bank ASA ARBN 675 447 702 is exempt from the requirement to hold an Australian financial services licence under the Corporations Act 2001 (Cth) ("Corporations Act") in respect of financial services it provides to "wholesale clients" within the meaning of the Corporations Act ("Wholesale Clients"). DNB Bank ASA accordingly does not hold an Australian financial services licence. DNB Bank ASA is regulated by Finanstilsynet (the Financial Supervisory Authority of Norway) under the laws of Norway, which differ from Australian laws.

This research report is provided only to authorised recipients who are both Wholesale Clients and "professional investors" within the meaning of the Corporations Act. In no circumstances may this research report be provided to any other person.

No member of the DNB Group, including DNB Bank ASA and DNB Carnegie Investment Bank AB, is an authorised deposit-taking institution ("ADI") under the Banking Act 1959 (Cth). Accordingly, neither DNB Bank ASA nor DNB Carnegie Investment Bank AB is supervised by the Australian Prudential Regulation Authority as an ADI.

DNB Bank ASA is a limited liability company incorporated in Norway.

Nothing in this research report excludes, restricts or modifies a statutory warranty or liability to the extent such an exclusion, restriction or modification would be prohibited under Australian law.

Additional information for clients in Canada

This research report and the information included herein is general investment advice that is not tailored to the needs of any recipient and, accordingly, is distributed to Canadian residents in reliance on section 8.25 of the Canadian Securities Administrators' National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. For disclosures regarding any financial or other interest that DNB Bank ASA, DNB Carnegie Investment Bank AB and their affiliates may have in the issuer or issuers that are the subject of this research report please see the potential conflict of interest section and the company-specific disclosures section.

Additional information for clients in Singapore

This research report is distributed by the Singapore Branch of DNB Bank ASA. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. Please seek advice from a financial adviser regarding the suitability of any product referred to in this research report, taking into account your specific financial objectives, financial situation or particular needs before making a commitment to purchase any such product or security. You have received a copy of this research report because you have been classified as an accredited investor, an expert investor, or as an institutional investor, as these terms have been defined under Singapore's Financial Advisers Act (Cap. 110) ("FAA") and/or the Financial Advisers Regulations ("FAR"). The Singapore Branch of DNB Bank ASA is a financial adviser exempt from licensing under the FAA but is otherwise subject to the legal requirements of the FAA and of the FAR. By virtue of your status as an accredited investor, institutional investor or as an expert investor, the Singapore Branch of DNB Bank ASA is, with respect to certain of its dealings with you or services rendered to you, exempt from having to comply with certain regulatory requirements of the FAA and FAR, including without limitation, sections 34, 36 and 45 of the FAA. Section 34 of the FAA requires a financial adviser to disclose material information concerning designated investment products that are recommended by the financial adviser to you as the client. Section 36 of the FAA requires a financial adviser to have a reasonable basis for making investment recommendations to you as the client. Section 45 of the FAA requires a financial adviser to include, within any circular or written communications in which they make recommendations concerning securities, a statement of the nature of any interest which the financial adviser (and any person connected or associated with the financial adviser) might have in the securities. Please contact the Singapore branch of DNB Bank ASA at +65 6260 0111 with respect to any matters arising from, or in connection with, this research report. This research report is intended for and is to be circulated only to people who are classified as an accredited investor, an expert investor, or an institutional investor. If you are not an accredited investor, an expert investor or an institutional investor, please contact the Singapore Branch of DNB Bank ASA at +65 6260 0111. DNB Bank ASA, its affiliates and subsidiaries, our associates, officers and/or employees may have interests in any products referred to in this research report by acting in various roles including as distributor, holder of principal positions, adviser or lender. DNB Bank ASA, its affiliates, subsidiaries, our associates, officers and/or employees may receive fees, brokerage or commissions for acting in those capacities. In addition, DNB Bank ASA, its affiliates and subsidiaries, our associates, officers and/or employees may buy or sell products as principal or agent and may effect transactions that are not consistent with the information set out in this research report.

Additional information for clients in the United States

The research analyst(s) named on this research report are foreign research analysts as defined by FINRA Rule 1220. The only affiliates contributing to this research report are the investment services division of DNB Bank ASA and DNB Carnegie Investment Bank AB (a wholly owned subsidiary of DNB Bank ASA) ("hereinafter DNB Carnegie"); the foreign research analysts employed by DNB Carnegie are named on the first page; the foreign research analysts are not registered/qualified as research analysts with FINRA; foreign research analysts are not associated persons of DNB Carnegie, Inc. and therefore are not subject to the restrictions set forth in FINRA Rules 2241 and 2242 regarding restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

This is a Third-Party Research Report as defined by FINRA Rules 2241 and 2242. Any material conflict of interest that can reasonably be expected to have influenced the choice of DNB Carnegie as a research provider or the Subject Company of a DNB Carnegie research report, including the disclosures required by FINRA Rules 2241 and 2242 can be found above.

This research report is being furnished solely to Major U.S. Institutional Investors within the meaning of Rule 15a-6 under the U.S. Securities Exchange Act of 1934 and to such other U.S. Institutional Investors as DNB Carnegie, Inc. may determine. Distribution to non-Major U.S. Institutional Investors will be made only by DNB Carnegie, Inc., a separately incorporated subsidiary of DNB Bank ASA which is a U.S. broker-dealer registered with the Securities and Exchange Commission ("SEC") and member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

Securities offered and sold in the U.S. are provided through DNB Carnegie, Inc. (SEC #8-66024 / CRD#127605).

Any U.S. recipient of this research report seeking to obtain additional information or to effect any transaction in any security discussed herein or any related instrument or investment should contact DNB Carnegie, Inc., 30 Hudson Yards, 81st Floor, New York, NY 10001, telephone number +1 212-551-9800.

At DNB Carnegie, we are dedicated to being the most respected partner for Nordic investment banking and wealth management solutions, leveraging the full capabilities of DNB. With unmatched strength across products, sectors, and geographies, our commitment is crystal clear: Clients first!

We deliver tailored financial solutions in mergers and acquisitions, capital markets, and financial advisory services by leveraging our deep market knowledge and expansive international reach. As an agile investment bank and part of a major Nordic banking group, we offer unparalleled local expertise, exceptional placing power, and a unique network.

Our roots run deep in the Nordic region, with strong local offices in Sweden, Norway, Denmark, and Finland. This solid foundation is amplified by our global presence in London, New York, and Singapore.

**DNB Bank ASA
DNB Carnegie**

Dronning Eufemias gate 30
0191 Oslo | Norway
Telephone: +47 915 04800

www.dnb.no

DNB Carnegie Investment Bank AB

Regeringsgatan 56
103 38 Stockholm | Sweden
Telephone: +46 8 676 88 00

www.dnbcarnegie.se

**DNB Carnegie Investment Bank,
Denmark Branch**

Overgaden neden Vandet 9B PO Box 1935
1414 Copenhagen K | Denmark
Telephone: +45 32 88 02 00

**DNB Bank ASA, Singapore Branch
DNB Carnegie**

1 Wallich Street Downtown Core 06
#30-01, Guoco Tower, Singapore 078881
Telephone: +65 6260 0111

**DNB Carnegie Investment Bank AB,
Finland Branch**

Eteläesplanadi 2 PO Box 36
FI-00131 Helsinki | Finland
Telephone: +358 9 618 71 230

**DNB Bank ASA, London Branch
DNB Carnegie**

The Walbrook Building, 25 Walbrook
London EC4N 8AF | England
Telephone: +44 20 7216 4000

**DNB Carnegie Investment Bank AB, UK
Branch**

The Walbrook Building, 25 Walbrook
London EC4N 8AF | England
Telephone: +44 20 7216 4000

DNB Carnegie, Inc.

30 Hudson Yards
New York, NY 10001 USA
Telephone: +1 212 551 9800